Leerink analyst Asthika Goonewardene resumes coverage on Genmab A/S (NASDAQ: GMAB) with a Outperform rating and a price target of $50.00.

For an analyst ratings summary and ratings history on Genmab A/S click here. For more ratings news on Genmab A/S click here.

Shares of Genmab A/S closed at $34.75 yesterday.